Core Insights - Abbott Laboratories (ABT) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, beating the Zacks Consensus Estimate by 0.8% and improving 10.5% year over year [2][8] - Despite strong earnings and revenue results, ABT stock fell 5% in pre-market trading due to cautious third-quarter guidance [2][8] Revenue Performance - Worldwide sales reached $11.14 billion, a 7.4% increase year over year, surpassing the Zacks Consensus Estimate by 0.6% [3][8] - Organic sales improved by 6.9% year over year, with organic sales excluding COVID-19 rising by 7.5% [3] Segment Analysis - Established Pharmaceuticals segment sales increased by 6.9% on a reported basis to $1.38 billion, with organic sales in emerging markets growing by 8.7% [4] - Medical Devices segment sales rose 13.4% year over year to $5.37 billion, driven by Diabetes Care and Structural Heart products [5][8] - Diabetes Care division reported organic sales growth of 19.6%, with continuous glucose monitors contributing $1.90 billion to total sales [6] - Nutrition sales rose 2.9% year over year to $2.21 billion, with Adult Nutrition benefiting from strong global growth [7] - Diagnostics sales declined 1% year over year to $2.17 billion, impacted by lower COVID-19 testing-related sales [9] Margin and Expense Details - Gross profit increased by 8.9% year over year to $6.29 billion, with gross margin expanding by 79 basis points to 56.4% [9][10] - Selling, general and administration expenses rose 5.3% to $3.09 billion, while research and development expenses increased by 3.9% to $725 million [10] Financial Guidance - For full-year 2025, Abbott expects adjusted diluted EPS in the range of $5.10-$5.20, with organic sales growth projected at 7.5-8.0% [11] - Third-quarter adjusted diluted EPS is expected to be between $1.28 and $1.32, slightly below the Zacks Consensus Estimate of $1.34 [12] Strategic Developments - Abbott announced favorable data from the AVEIR Conduction System Pacing clinical study and received FDA approval for its Tendyne transcatheter mitral valve replacement system [14] - Plans to develop a new cardiovascular device manufacturing facility in Georgia, expected to be completed by 2028 [14]

for more on the markets and how investors uh may want to position themselves in the second half of the year. We are joined now by Charmine Mosa Mosavar. I always I always butcher your name.It kills me. It kills me. Uh kills me.It I know it's it's it's horrible. Chief investment officer uh for Goldman Sachs Wealth Management. Good morning to you. Good morning.We've got I'm happy to go by my first name. That's okay, too. You can just say we've known each other a long time and every time I You know what it is. ...

Volvo reported better-than expected second-quarter earnings as signs of a recovery in Europe helped offset weak demand for trucks in North America https://t.co/yKDcLyh9fB ...

there's a sense, okay, we had the initial reaction, now we've kind of recovered, maybe people were overreacting and they we shouldn't take this threat too seriously. How does it fit in with everything else that's going on here. Yeah, I think we could look at the tariffs and the market's reaction uh as a bogey here, which is it went from, oh my god, where this is heading to until something becomes law and it's implemented, let's count it as noise, right.And uh the important thing here is that it's clear that ...

Stock futures were mixed Wednesday as Bank of America reported mixed results and earnings kept rolling in. Bitcoin moved higher on optimism that Congress would move forward with crypto legislation. Here's what investors need to know today. https://t.co/AKvM9mZoat ...

Token Buyback & Revenue Share - Pump 团队已开始在公开市场上回购 $PUMP [1] - $PUMP 持有者根据 180 天的追踪数据，每天获得 538,000 美元的回购（假设 25% 的收入分成）[1] - 相当于每年 1.966 亿美元直接流向代币持有者 [1] Valuation - 当前估值：60 亿美元完全稀释估值 (FDV) / 21.2 亿美元市值 [1] - 市值/收益 (MC/E)：10.78 倍（180 天）[1] - 完全稀释估值/收益 (FDV/E)：30.51 倍（180 天）[1] Peer Comparison - $JUP 的市值/收益 (MC/E) 为 14.17 倍，完全稀释估值/收益 (FDV/E) 为 32.33 倍 [1] - $RAY 的市值/收益 (MC/E) 为 13.09 倍，完全稀释估值/收益 (FDV/E) 为 27.08 倍 [1] - $HYPE 的市值/收益 (MC/E) 为 26.78 倍，完全稀释估值/收益 (FDV/E) 为 80.24 倍 [1] - 对比显示 Pump 的交易价格存在折价 [1]

Market Expectations & Potential Catalysts - Optimism is high for large-cap banks' Q2 earnings, with focus on loan growth and investment banking activity in the second half of the year [2][3] - IPO market recovery is seen as a potential catalyst for investment banks [3] - High valuations (e g, Bank of America trading at a PE of around 15) suggest caution going into earnings announcements [4] - Regulatory changes are a significant driver for bank stock movements this year [6] Key Metrics & Risk Factors - Net interest income growth, impacted by net interest margin, is a key focus [9] - Credit quality remains generally good, but commercial real estate office market and low FICO score consumers are potential areas of concern [8] - Risk-on sentiment suggests less concern about credit picture, while risk-off would increase focus on credit [7][8] Mergers and Acquisitions - Industry expects consolidation among regional banks due to deregulation [13] - The top 5-7 banks control 85-90% of the assets, with smaller banks controlling the rest, indicating increased polarization in banking [14] - Potential for big regionals to merge or be acquired by G-SIBs exists [15] - Clarity on Basel III endgame proposal is needed before M&A activity accelerates [15] Leadership Transition - Jamie Dimon's leadership has significantly impacted JP Morgan's stock [10] - Jamie Dimon's eventual retirement will likely negatively impact the stock on the day of the announcement [12] - Marianne Lake is considered a potential successor to Jamie Dimon [11]

City Croup, a US equity strategist Scott Croner's with us at Post9 as we get set for earnings season to kick into higher gear. Good to see you, Scott. Welcome.Great to be here, Carl. Um, is the market really just focused on on Q2 earnings. Well, I think it's focused on Q2 earnings, but I actually think it's increasingly focused on the follow through and the aftermath of tariffs and other policy news in terms of what it means for 2026.As we go in the back half of the year, you usually flip forward on the cal ...

All right, June CPI data is due out tomorrow. That's the same day the big bank earnings kickoff with JP Morgan City and Wells Fargo results. For more on those markets, we want to bring in Ed Yardeni.He's the president of Yard Denny Research. Uh Ed, how you feeling about things right now. I'm feeling pretty good about bank earnings.I think uh loans have uh started to improve. Uh there's obviously been a lot of activity uh in the capital markets. The equity market has had a great rally.Uh, Wall Street's prett ...

Trade and Tariffs - Potential new tariffs on the EU and Mexico starting August 1st are being considered, primarily as a negotiating tactic to achieve broader policy goals beyond just trade [1][5] - The market impact of these potential tariffs on European markets has been limited, possibly because investors view them as temporary threats [3] - The shift from free trade to "friend trade" reflects a broader strategy of prioritizing close relationships in global trade [2] Earnings and Market Outlook - Earnings season is approaching, with a positive outlook expected later in the year, potentially boosted by a 10%+ move in the dollar [7] - AI is expected to drive cost reduction and margin improvement for smaller companies, potentially starting next year [8][11] - Tech and communication services are driving most of the earnings growth; without them, overall earnings growth would be negative [9] Investment Opportunities - Smaller value companies outside the Mag 7, trading at 13-14 times earnings, may benefit from AI adoption [11] - In Europe, investment opportunities exist in defense and infrastructure sectors due to increased spending [13][14] - In Asia, tech-oriented markets are preferred over goods-dependent markets due to potential tariff impacts [16][17] Market Valuation - The Mag 7 stocks are trading at approximately 31 times forward earnings, while the rest of the market is just under 21 times [9] - The earnings growth spread between the Mag 7 and the rest of the market is compressing, suggesting potential outperformance of smaller caps [10][11]